Skip to main content
NCBI home page
NeuroRx logoLink to NeuroRx
. 2012 Sep 5;3(1):117–130. doi: 10.1016/j.nurx.2005.12.001

Imaging genomics and response to treatment with antipsychotics in schizophrenia

Giuseppe Blasi 1,2, Alessandro Bertolino 1,2,3,✉
PMCID: PMC3593360  PMID: 16490418

Abstract

Recent important advancements in genomic research have opened the way to new strategies for public health management. One of these questions pertains to how individual genetic variation may be associated with individual variability in response to drug treatment. The field of pharmacogenetics may have a profound impact on treatment of complex psychiatric disorders like schizophrenia. However, pharmacogenetic studies in schizophrenia have produced conflicting results. The first studies examined potential associations between clinical response and drug receptor genes. Subsequent studies have tried to use more objective phenotypes still in association with drug receptor genes. More recently, other studies have sought the association between putative causative or modifier genes and intermediate phenotypes. Thus, conflicting results may be at least in part explained by variability and choice of the phenotype, by choice of candidate genes, or by the relatively little knowledge about the neurobiology of this disorder. We propose that choosing intermediate phenotypes that allow in vivo measurement of specific neuronal functions may be of great help in reducing several of the potential confounds intrinsic to clinical measurements. Functional neuroimaging is ideally suited to address several of these potential confounds, and it may represent a powerful strategy to investigate the relationship between behavior, brain function, genes, and individual variability in the response to treatment with antipsychotic drugs in schizophrenia. Preliminary evidence with potential susceptilibity genes such as COMT, DISC1, and GRM3 support these assumptions.

Key Words: Imaging genomics, antipsychotics, schizophrenia, fMRI, PET, COMT, DISC1, GRM3

References

  • 1.McGuffin P, Riley B, Plomin R. Genomics and behavior. Toward behavioral genomics. Science. 2001;5507:1232–1249. doi: 10.1126/science.1057264. [DOI] [PubMed] [Google Scholar]
  • 2.Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005;1:40–68. doi: 10.1038/sj.mp.4001558. [DOI] [PubMed] [Google Scholar]
  • 3.Lewis CM, Levinson DF, Wise LH, Delisi LE, Straub RE, Hovatta I, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder. Part II: schizophrenia. Am J Hum Genet. 2003;1:34–48. doi: 10.1086/376549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry. 2002;4:405–411. doi: 10.1038/sj.mp.4001012. [DOI] [PubMed] [Google Scholar]
  • 5.Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;7:660–669. doi: 10.1001/archpsyc.1987.01800190080012. [DOI] [PubMed] [Google Scholar]
  • 6.Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci. 1998;7:2697–2708. doi: 10.1523/JNEUROSCI.18-07-02697.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci. 2002;2:389–395. doi: 10.1523/JNEUROSCI.22-02-00389.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Shen HW, Hagino Y, Kobayashi H, Shinohara-Tanaka K, Ikeda K, Yamamoto H, et al. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology. 2004;10:1790–1799. doi: 10.1038/sj.npp.1300476. [DOI] [PubMed] [Google Scholar]
  • 9.Tunbridge EM, Bannerman DM, Sharp T, Harrison PJ. Catecholo-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci. 2004;23:5331–5335. doi: 10.1523/JNEUROSCI.1124-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Liljequist R, Haapalinna A, Ahlander M, Li YH, Mannisto PT. Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. Behav Brain Res. 1997;2:195–202. doi: 10.1016/s0166-4328(97)80989-8. [DOI] [PubMed] [Google Scholar]
  • 11.Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA. 1998;17:9991–9996. doi: 10.1073/pnas.95.17.9991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 1999;4:593–628. [PubMed] [Google Scholar]
  • 13.Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol. 2004;1:1–58. doi: 10.1016/j.pneurobio.2004.05.006. [DOI] [PubMed] [Google Scholar]
  • 14.Goldman-Rakic PS. The cortical dopamine system: role in memory and cognition. Adv Pharmacol 707–711, 1998. [DOI] [PubMed]
  • 15.Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA. 2001;12:6917–6922. doi: 10.1073/pnas.111134598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS, et al. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Vall58Met genotype and schizophrenia. Arch Gen Psychiatry. 2003;9:889–896. doi: 10.1001/archpsyc.60.9.889. [DOI] [PubMed] [Google Scholar]
  • 17.Blasi G, Mattay VS, Bertolino A, Elvevag B, Callicott JH, Das S, et al. Effect of catechol-O-methyltransferase val158met genotype on attentional control. J Neurosci. 2005;20:5038–5045. doi: 10.1523/JNEUROSCI.0476-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Bearden CE, Jawad AF, Lynch DR, Sokol S, Kanes SJ, McDonald-McGinn DM, et al. Effects of a functional COMT polymorphism on prefrontal cognitive function in patients with 22ql 1.2 deletion syndrome. Am J Psychiatry. 2004;9:1700–1702. doi: 10.1176/appi.ajp.161.9.1700. [DOI] [PubMed] [Google Scholar]
  • 19.Diamond A, Briand L, Fossella J, Gehlbach L. Genetic and neurochemical modulation of prefrontal cognitive functions in children. Am J Psychiatry. 2004;1:125–132. doi: 10.1176/appi.ajp.161.1.125. [DOI] [PubMed] [Google Scholar]
  • 20.Callicott JH, Bertolino A, Mattay VS, Langheim FJ, Duyn J, Coppola R, et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex. 2000;11:1078–1092. doi: 10.1093/cercor/10.11.1078. [DOI] [PubMed] [Google Scholar]
  • 21.Manoach DS, Gollub RL, Benson ES, Searl MM, Goff DC, Halpern E, et al. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol Psychiatry. 2000;2:99–109. doi: 10.1016/s0006-3223(00)00227-4. [DOI] [PubMed] [Google Scholar]
  • 22.Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V, et al. Interaction of COMT Vall08/158 Met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry. 2004;10:1798–1805. doi: 10.1176/ajp.161.10.1798. [DOI] [PubMed] [Google Scholar]
  • 23.Ho BC, Wassink TH, O’Leary DS, Sheffield VC, Andreasen NC. Catechol-O-methyl transferase Val158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow. Mol Psychiatry. 2005;3(229):287–298. doi: 10.1038/sj.mp.4001616. [DOI] [PubMed] [Google Scholar]
  • 24.St Clair D, Blackwood D, Muir W, Carothers A, Walker M, Spowart G, et al. Association within a family of a balanced autosomal translocation with major mental illness. Lancet. 1990;8706:13–16. doi: 10.1016/0140-6736(90)91520-k. [DOI] [PubMed] [Google Scholar]
  • 25.Devon RS, Anderson S, Teague PW, Burgess P, Kipari TM, Semple CA, et al. Identification of polymorphisms within Disrupted in Schizophrenia 1 and Disrupted in Schizophrenia 2, and an investigation of their association with schizophrenia and bipolar affective disorder. Psychiatr Genet. 2001;2:71–78. doi: 10.1097/00041444-200106000-00003. [DOI] [PubMed] [Google Scholar]
  • 26.Hennah W, Varilo T, Kestila M, Paunio T, Arajarvi R, Haukka J, et al. Haplotype transmission analysis provides evidence of association for DISC1 to schizophrenia and suggests sex-dependent effects. Hum Mol Genet. 2003;23:3151–3159. doi: 10.1093/hmg/ddg341. [DOI] [PubMed] [Google Scholar]
  • 27.Ekelund J, Hennah W, Hiekkalinna T, Parker A, Meyer J, Lonnqvist J, et al. Replication of 1q42 linkage in Finnish schizophrenia pedigrees. Mol Psychiatry. 2004;11:1037–1041. doi: 10.1038/sj.mp.4001536. [DOI] [PubMed] [Google Scholar]
  • 28.Hodgkinson CA, Goldman D, Jaeger J, Persaud S, Kane JM, Lipsky RH, et al. Disrupted in Schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet. 2004;5:862–872. doi: 10.1086/425586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Sachs NA, Sawa A, Holmes SE, Ross CA, Delisi LE, Margolis RL. A frameshift mutation in disrupted in schizophrenia 1 in an American family with schizophrenia and schizo affective disorder. Mol Psychiatry. 2005;10:758–764. doi: 10.1038/sj.mp.4001667. [DOI] [PubMed] [Google Scholar]
  • 30.Thomson PA, Wray NR, Millar JK, Evans KL, Hellard SL, Condie A, et al. Association between the TRAX/DISC locus and both bipolar disorder and schizophrenia in the Scottish population. Mol Psychiatry. 2005;7(616):657–668. doi: 10.1038/sj.mp.4001669. [DOI] [PubMed] [Google Scholar]
  • 31.Morris JA, Kandpal G, Ma L, Austin CP. DISC1 (Disrupted-In-Schizophrenia 1) is a centra some-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation. Hum Mol Genet. 2003;13:1591–1608. doi: 10.1093/hmg/ddg162. [DOI] [PubMed] [Google Scholar]
  • 32.Austin CP, Ky B, Ma L, Morris JA, Shughrue PJ. Expression of Disrupted-In-Schizophrenia-1, a schizophrenia-associated gene, is prominent in the mouse hippocampus throughout brain development. Neuroscience. 2004;1:3–10. doi: 10.1016/j.neuroscience.2003.11.010. [DOI] [PubMed] [Google Scholar]
  • 33.Callicott JH, Straub RE, Pezawas L, Egan MF, Mattay VS, Hariri AR, et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci USA. 2005;24:8627–8632. doi: 10.1073/pnas.0500515102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Bunney BS, Chiodo LA, Grace AA. Midbrain dopamine system electro physiological functioning: a review and new hypothesis. Synapse. 1991;2:79–94. doi: 10.1002/syn.890090202. [DOI] [PubMed] [Google Scholar]
  • 35.Deakin JF, Slater P, Simpson MD, Gilchrist AC, Skan WJ, Royston MC, et al. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem. 1989;6:1781–1786. doi: 10.1111/j.1471-4159.1989.tb07257.x. [DOI] [PubMed] [Google Scholar]
  • 36.Nishikawa T, Takashima M, Toru M. Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett. 1983;3:245–250. doi: 10.1016/0304-3940(83)90046-0. [DOI] [PubMed] [Google Scholar]
  • 37.Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 1995;10:829–836. doi: 10.1001/archpsyc.1995.03950220039008. [DOI] [PubMed] [Google Scholar]
  • 38.Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem. 2000;3:889–907. doi: 10.1046/j.1471-4159.2000.0750889.x. [DOI] [PubMed] [Google Scholar]
  • 39.Aronica E, Goiter JA, Ijlst-Keizers H, Rozemuller AJ, Yankaya B, Leenstra S, et al. Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur J Neurosci. 2003;10:2106–2118. doi: 10.1046/j.1460-9568.2003.02657.x. [DOI] [PubMed] [Google Scholar]
  • 40.Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996;3:675–686. doi: 10.1016/s0896-6273(00)80086-0. [DOI] [PubMed] [Google Scholar]
  • 41.Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998;5381:1349–1352. doi: 10.1126/science.281.5381.1349. [DOI] [PubMed] [Google Scholar]
  • 42.Ohnuma T, Tessler S, Arai H, Faull RL, McKenna PJ, Emson PC. Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Brain Res Mol Brain Res. 2000;1–2:24–31. doi: 10.1016/s0169-328x(00)00222-9. [DOI] [PubMed] [Google Scholar]
  • 43.Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR, et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA. 2004;34:12604–12609. doi: 10.1073/pnas.0405077101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Fujii Y, Shibata H, Kikuta R, Makino C, Tani A, Hirata N, et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet. 2003;2:71–16. doi: 10.1097/01.ypg.0000056682.82896.b0. [DOI] [PubMed] [Google Scholar]
  • 45.Chen Q, He G, Wu S, Xu Y, Feng G, Li Y, et al. A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. Schizophr Res. 2005;1:21–26. doi: 10.1016/j.schres.2004.07.002. [DOI] [PubMed] [Google Scholar]
  • 46.Bertolino A, Nawroz S, Mattay VS, Barnett AS, Duyn JH, Moonen CT, et al. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry. 1996;12:1554–1563. doi: 10.1176/ajp.153.12.1554. [DOI] [PubMed] [Google Scholar]
  • 47.Marti SB, Cichon S, Propping P, Nothen M. Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am J Med Genet. 2002;1:46–50. doi: 10.1002/ajmg.1624. [DOI] [PubMed] [Google Scholar]
  • 48.Norton N, Williams HJ, Dwyer S, Ivanov D, Preece AC, Gerrish A, et al. No evidence for association between polymorphisms in GRM3 and schizophrenia. BMC Psychiatry. 2005;1:23–23. doi: 10.1186/1471-244X-5-23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Lu B, Gottschalk W. Modulation of hippocampal synaptic transmission and plasticity by neurotrophins. Prog Brain Res. 2000;128:231–241. doi: 10.1016/S0079-6123(00)28020-5. [DOI] [PubMed] [Google Scholar]
  • 50.Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci. 2001;1:24–32. doi: 10.1038/35049004. [DOI] [PubMed] [Google Scholar]
  • 51.Gottschalk W, Pozzo-Miller LD, Figurov A, Lu B. Presynaptic modulation of synaptic transmission and plasticity by brain-derived neurotrophic factor in the developing hippocampus. J Neurosci. 1998;17:6830–6839. doi: 10.1523/JNEUROSCI.18-17-06830.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Gottschalk WA, Jiang H, Tartaglia N, Feng L, Figurov A, Lu B. Signaling mechanisms mediating BDNF modulation of synaptic plasticity in the hippocampus. Learn Mem. 1999;3:243–256. [PMC free article] [PubMed] [Google Scholar]
  • 53.Jovanovic JN, Czernik AJ, Fienberg AA, Greengard P, Sihra TS. Synapsins as mediators of BDNF-enhanced neurotransmitter release. Nat Neurosci. 2000;4:323–329. doi: 10.1038/73888. [DOI] [PubMed] [Google Scholar]
  • 54.Pozzo-Miller LD, Gottschalk W, Zhang L, McDermott K, Du J, Gopalakrishnan R, et al. Impairments in high-frequency transmission, synaptic vesicle docking, and synaptic protein distribution in the hippocampus of BDNF knockout mice. J Neurosci. 1999;12:4972–4983. doi: 10.1523/JNEUROSCI.19-12-04972.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Xu B, Gottschalk W, Chow A, Wilson RI, Schnell E, Zang K, et al. The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving TrkB. J Neurosci. 2000;18:6888–6897. doi: 10.1523/JNEUROSCI.20-18-06888.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Linnarsson S, Bjorklund A, Ernfors P. Learning deficit in BDNF mutant mice. Eur J Neurosci. 1997;12:2581–2587. doi: 10.1111/j.1460-9568.1997.tb01687.x. [DOI] [PubMed] [Google Scholar]
  • 57.Minichiello L, Korte M, Wolfer D, Kuhn R, Unsicker K, Cestari V, et al. Essential role for TrkB receptors in hippocampus-mediated learning. Neuron. 1999;2:401–414. doi: 10.1016/s0896-6273(00)80853-3. [DOI] [PubMed] [Google Scholar]
  • 58.Mizuno M, Yamada K, Olariu A, Nawa H, Nabeshima T. Involvement of brain-derived neurotrophic factorin spatial memory formation and maintenance in a radial arm maze test in rats. J Neurosci. 2000;18:7116–7121. doi: 10.1523/JNEUROSCI.20-18-07116.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Angelucci F, Brene S, Mathe AA. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry. 2005;4:345–352. doi: 10.1038/sj.mp.4001637. [DOI] [PubMed] [Google Scholar]
  • 60.Callicott JH, Egan MF, Bertolino A, Mattay VS, Langheim FJ, Frank JA, et al. Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biol Psychiatry. 1998;10:941–950. doi: 10.1016/s0006-3223(98)00264-9. [DOI] [PubMed] [Google Scholar]
  • 61.Hattori M, Kunugi H, Akahane A, Tanaka H, Ishida S, Hirose T, et al. Novel polymorphisms in the promoter region of the neurotrophin-3 gene and their associations with schizophrenia. Am J Med Genet. 2002;3:304–309. doi: 10.1002/ajmg.10248. [DOI] [PubMed] [Google Scholar]
  • 62.Jonsson E, Brene S, Zhang XR, Nimgaonkar VL, Tylec A, Schalling M, et al. Schizophrenia and neurotrophin-3 alleles. Acta Psychiatr Scand. 1997;5:414–419. doi: 10.1111/j.1600-0447.1997.tb09654.x. [DOI] [PubMed] [Google Scholar]
  • 63.Szekeres G, Juhasz A, Rimanoczy A, Keri S, Janka Z. The C270T polymorphism of the brain-derived neurotrophic factor gene is associated with schizophrenia. Schizophr Res. 2003;1:15–18. doi: 10.1016/s0920-9964(02)00505-4. [DOI] [PubMed] [Google Scholar]
  • 64.Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;2:257–269. doi: 10.1016/s0092-8674(03)00035-7. [DOI] [PubMed] [Google Scholar]
  • 65.Neves-Pereira M, Cheung JK, Pasdar A, Zhang F, Breen G, Yates P, et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry. 2005;2:208–212. doi: 10.1038/sj.mp.4001575. [DOI] [PubMed] [Google Scholar]
  • 66.Szczepankiewicz A, Skibinska M, Czerski PM, Kapelski P, Leszczynska-Rodziewicz A, Slopien A, et al. No association of the brain-derived neurotrophic factor (BDNF) gene C-270T polymorphism with schizophrenia. Schizophr Res. 2005;2–3:187–193. doi: 10.1016/j.schres.2005.02.006. [DOI] [PubMed] [Google Scholar]
  • 67.de Krom M, Bakker SC, Hendriks J, van Elburg A, Hoogendoorn M, Verduijn W, et al. Polymorphisms in the brain-derived neurotrophic factor gene are not associated with either anorexia nervosa or schizophrenia in Dutch patients. Psychiatr Genet. 2005;2:81–81. doi: 10.1097/00041444-200506000-00003. [DOI] [PubMed] [Google Scholar]
  • 68.Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci. 2003;17:6690–6694. doi: 10.1523/JNEUROSCI.23-17-06690.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci. 2004;45:10099–10102. doi: 10.1523/JNEUROSCI.2680-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Szeszko PR, Lipsky R, Mentschel C, Robinson D, Gunduz-Bruce H, Sevy S, et al. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol Psychiatry. 2005;7:631–636. doi: 10.1038/sj.mp.4001656. [DOI] [PubMed] [Google Scholar]
  • 71.Malhotra AK, Murphy GM, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry. 2004;5:780–796. doi: 10.1176/appi.ajp.161.5.780. [DOI] [PubMed] [Google Scholar]
  • 72.Schafer M, Rujescu D, Giegling I, Guntermann A, Erfurth A, Bondy B, et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry. 2001;5:802–804. doi: 10.1176/appi.ajp.158.5.802. [DOI] [PubMed] [Google Scholar]
  • 73.Suzuki A, Mihara K, Kondo T, Tanaka O, Nagashima U, Otani K, et al. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics. 2000;4:335–341. doi: 10.1097/00008571-200006000-00007. [DOI] [PubMed] [Google Scholar]
  • 74.Suzuki A, Kondo T, Mihara K, Yasui-Furukori N, Ishida M, Furukori H, et al. The −141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics. 2001;6:545–550. doi: 10.1097/00008571-200108000-00009. [DOI] [PubMed] [Google Scholar]
  • 75.Arranz MJ, Li T, Munro J, Liu X, Murray R, Collier DA, et al. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics. 1998;6:481–484. doi: 10.1097/00008571-199812000-00004. [DOI] [PubMed] [Google Scholar]
  • 76.Kapur S, Agid O, Mizrahi R, Li M. How anitpsychotics work-from receptors to reality. NeuroRx. 2006;3:10–21. doi: 10.1016/j.nurx.2005.12.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Gessa GL, Devoto P, Diana M, Flore G, Melis M, Pistis M. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology. 2000;6:642–649. doi: 10.1016/S0893-133X(00)00087-7. [DOI] [PubMed] [Google Scholar]
  • 78.Diaz-Asper C, Goldberg T. COMT polymorphism and prefrontal cognitive function. NeuroRx. 2006;3:97–105. doi: 10.1016/j.nurx.2005.12.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Weickert TW, Goldberg TE, Mishara A, Apud JA, Kolachana BS, Egan MF, et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry. 2004;9:677–682. doi: 10.1016/j.biopsych.2004.08.012. [DOI] [PubMed] [Google Scholar]
  • 80.Bishop JR, Ellingrod VL, Moline J, Miller D. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res. 2005;77:253–60. doi: 10.1016/j.schres.2005.04.001. [DOI] [PubMed] [Google Scholar]
  • 81.Krebs MO, Guillin O, Bourdell MC, Schwartz JC, Olie JP, Poirier MF, et al. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry. 2000;5:558–562. doi: 10.1038/sj.mp.4000749. [DOI] [PubMed] [Google Scholar]
  • 82.Hong CJ, Yu YW, Lin CH, Tsai SJ. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci Lett. 2003;3:206–208. doi: 10.1016/s0304-3940(03)00828-0. [DOI] [PubMed] [Google Scholar]
  • 83.Anttila S, Illi A, Kampman O, Mattila KM, Lehtimaki T, Leinonen E. Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics. J Neural Transm. 2005;7:885–890. doi: 10.1007/s00702-004-0233-9. [DOI] [PubMed] [Google Scholar]
  • 84.Corson PW, Nopoulos P, Miller DD, Arndt S, Andreasen NC. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am J Psychiatry. 1999;8:1200–1204. doi: 10.1176/ajp.156.8.1200. [DOI] [PubMed] [Google Scholar]
  • 85.Scheepers FE, de Wied CC, Hulshoff Pol HE, van de Flier W, van der Linden JA, Kahn RS. The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical anti psychotics. Neuropsychopharmacology. 2001;1:47–54. doi: 10.1016/S0893-133X(00)00172-X. [DOI] [PubMed] [Google Scholar]
  • 86.Scheepers FE, Gispen de Wied CC, Hulshoff Pol HE, Kahn RS. Effect of clozapine on caudate nucleus volume in relation to symptoms of schizophrenia. Am J Psychiatry. 2001;4:644–646. doi: 10.1176/appi.ajp.158.4.644. [DOI] [PubMed] [Google Scholar]
  • 87.Lang DJ, Kopala LC, Vandorpe RA, Rui Q, Smith GN, Goghari VM, et al. AnMRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone. Am J Psychiatry. 2001;4:625–631. doi: 10.1176/appi.ajp.158.4.625. [DOI] [PubMed] [Google Scholar]
  • 88.Lang DJ, Kopala LC, Vandorpe RA, Rui Q, Smith GN, Goghari VM, et al. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia. Am J Psychiatry. 2004;10:1829–1836. doi: 10.1176/ajp.161.10.1829. [DOI] [PubMed] [Google Scholar]
  • 89.Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005;4:361–370. doi: 10.1001/archpsyc.62.4.361. [DOI] [PubMed] [Google Scholar]
  • 90.Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of Haloperidol and Olanzapine in Macaque monkeys. Neuropsychopharmacology. 2005;9:1649–1661. doi: 10.1038/sj.npp.1300710. [DOI] [PubMed] [Google Scholar]
  • 91.Fukuzako H, Fukuzako T, Kodama S, Hashiguchi T, Takigawa M, Fujimoto T. Haloperidol improves membrane phospholipid abnormalities in temporal lobes of schizophrenic patients. Neuropsychopharmacology. 1999;4:542–549. doi: 10.1016/S0893-133X(99)00050-0. [DOI] [PubMed] [Google Scholar]
  • 92.Bertolino A, Callicott JH, Mattay VS, Weidenhammer KM, Rakow R, Egan MF, et al. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol Psychiatry. 2001;1:39–46. doi: 10.1016/s0006-3223(00)00997-5. [DOI] [PubMed] [Google Scholar]
  • 93.Liddle PF, Lane CJ, Ngan ET. Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus. Br J Psychiatry 402–407, 2000 [DOI] [PubMed]
  • 94.Bartlett EJ, Brodie JD, Simkowitz P, Schlosser R, Dewey SL, Lindenmayer JP, et al. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. Am J Psychiatry. 1998;3:337–343. doi: 10.1176/ajp.155.3.337. [DOI] [PubMed] [Google Scholar]
  • 95.Molina V, Gispert JD, Reig S, Sanz J, Pascau J, Santos A, et al. Cerebral metabolism and risperidone treatment in schizophrenia. Schizophr Res. 2003;1:1–7. doi: 10.1016/s0920-9964(02)00199-8. [DOI] [PubMed] [Google Scholar]
  • 96.Molina V, Gispert JD, Reig S, Sanz J, Pascau J, Santos A, et al. Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. Psychopharmacology (Berl) 2005;1:17–26. doi: 10.1007/s00213-004-1981-9. [DOI] [PubMed] [Google Scholar]
  • 97.Rodriguez VM, Andrée RM, Castejon MJ, Zamora ML, Alvaro PC, Delgado JL, et al. Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory schizophrenic patients. A 99mTc-HMPAO study. Psychiatry Res. 1997;1:51–61. doi: 10.1016/s0925-4927(97)00057-7. [DOI] [PubMed] [Google Scholar]
  • 98.Lahti AC, Holcomb HH, Weiler MA, Medoff DR, Frey KN, Hardin M, et al. Clozapine but not haloperidol re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology. 2004;1:171–178. doi: 10.1038/sj.npp.1300312. [DOI] [PubMed] [Google Scholar]
  • 99.Molina V, Gispert JD, Reig S, Pascau J, Martinez R, Sanz J, et al. Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia. Int Clin Psychopharmacol. 2005;1:13–18. doi: 10.1097/00004850-200501000-00003. [DOI] [PubMed] [Google Scholar]
  • 100.Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci USA. 1999;23:13432–13437. doi: 10.1073/pnas.96.23.13432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Mattay VS, Callicott JH, Bertolino A, Santha AK, Tallent KA, Goldberg TE, et al. Abnormal functional lateralization of the sensorimotor cortex in patients with schizophrenia. Neuroreport. 1997;13:2977–2984. doi: 10.1097/00001756-199709080-00034. [DOI] [PubMed] [Google Scholar]
  • 102.Stephan KE, Magnotta VA, White T, Arndt S, Flaum M, O’Leary DS, et al. Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task. Psychol Med. 2001;6:1065–1078. doi: 10.1017/s0033291701004330. [DOI] [PubMed] [Google Scholar]
  • 103.Bertolino A, Blasi G, Caforio G, Latorre V, DeCandia M, Rubino V, et al. Functional lateralization of the sensorimotor cortex in patients with schizophrenia: effects of treatment with olanzapine. Biol Psychiatry. 2004;3:190–197. doi: 10.1016/j.biopsych.2004.04.009. [DOI] [PubMed] [Google Scholar]
  • 104.Stip E, Fahim C, Mancini-Marie A, Bentaleb LA, Mensour B, Mendrek A, et al. Restoration of frontal activation during a treatment with quetiapine: an fMRI study of blunted affect in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005;1:21–26. doi: 10.1016/j.pnpbp.2004.08.015. [DOI] [PubMed] [Google Scholar]
  • 105.Potkin SG, Basile VS, Jin Y, Masellis M, Badri F, Keator D, et al. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry. 2003;1:109–113. doi: 10.1038/sj.mp.4001191. [DOI] [PubMed] [Google Scholar]
  • 106.Bertolino A, Caforio G, Petruzzella V, Latorre V, Rubino V, Dimalta S, et al. GRM3 genotype and olanzapine treatment: Differential effects on prefrontal cortical function during working memory in patients with schizophrenia. Biol Psychiatry. 2005;8:S293–S293. [Google Scholar]
  • 107.Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci. 2002;9:3708–3719. doi: 10.1523/JNEUROSCI.22-09-03708.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Bilder RM, Volavka J, Lachman HM, Grace AA. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatrie phenotypes. Neuropsychopharmacology. 2004;11:1943–1961. doi: 10.1038/sj.npp.1300542. [DOI] [PubMed] [Google Scholar]
  • 109.Stahl S. Finding what you are not looking for: strategies for developing novel treatments in psychiatry. NeuroRx. 2006;3:3–9. doi: 10.1016/j.nurx.2005.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Goldberg TE, Weinberger DR. Genes and the parsing of cognitive processes. Trends Cogn Sci. 2004;7:325–335. doi: 10.1016/j.tics.2004.05.011. [DOI] [PubMed] [Google Scholar]

Articles from NeuroRx are provided here courtesy of Am. Soc. for Experimental NeuroTherapeutics

RESOURCES